GSK revenue and financials
Secondary listing. The primary listing is GSK · LSE (GBp)
$46.60Change from previous close: +0.11%Absolute change: +$0.05
In the fiscal year ended December 2025, GSK reported revenue of £32.67B (+4.11% year over year). Net income was £5.72B, a net margin of 17.5%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +4.11%
- 2025 vs 2024
- Net income growth
- +121.98%
- 2025 vs 2024
- Net margin
- 17.5%
- 2024: 8.2%
Financial data
Amounts in millions of GBP; per-share values in GBP; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 7,741 | 6,554 | 6,768 | 7,403 | 7,952 | 8,441 | 8,020 | 8,421 | 6,918 | 6,497 |
| Depreciation and amortization | 2,314 | 2,551 | 2,294 | 2,147 | 2,122 | 2,050 | 2,334 | 1,856 | 1,922 | 1,774 |
| Capital expenditure | -1,348 | -1,399 | -1,314 | -1,143 | -950 | -989 | -1,265 | -1,344 | -1,545 | -1,543 |
| Investing cash flow | -4,233 | -1,229 | -1,595 | -8,772 | -1,777 | — | — | — | — | — |
| Financing cash flow | -3,685 | -4,726 | -5,641 | 823 | -7,589 | — | — | — | — | — |
| Dividends paid | -2,564 | -2,444 | -2,247 | -3,467 | -3,999 | — | — | — | 3,906 | — |
| Share repurchases | -1,377 | 0.0 | 0.0 | — | — | — | — | — | — | — |
| Debt issued | 3,194 | 1,341 | 223 | 2,046 | 301 | — | — | — | — | — |
| Debt repaid | -1,929 | -2,733 | -2,790 | -6,870 | -2,485 | — | — | — | — | — |
| Effect of exchange rates | -19.0 | -54.0 | -99.0 | 152 | -29.0 | — | — | — | — | — |
| Net change in cash | -196 | 545 | -567 | -394 | -1,443 | — | — | — | — | — |
| Free cash flow | 6,393 | 5,155 | 5,454 | 6,260 | 7,002 | — | — | — | — | — |
| Levered free cash flow | 3,284 | 4,954 | 3,837 | 4,266 | 4,847 | — | — | — | — | — |